Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer - guidance (TA628)

Lorlatinib is recommended for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in disease that has progressed after, alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) or, crizotinib and at least one other ALK TKI.

National Institute for Health and Care Excellence